Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 198.35 Million CHF | -24.37% |
| 2022 | 262.25 Million CHF | 51.89% |
| 2021 | 172.66 Million CHF | -7.93% |
| 2020 | 187.54 Million CHF | 78.73% |
| 2019 | 104.93 Million CHF | -32.37% |
| 2018 | 155.15 Million CHF | 7.43% |
| 2017 | 144.42 Million CHF | -21.55% |
| 2016 | 184.09 Million CHF | -16.09% |
| 2015 | 219.39 Million CHF | 13.08% |
| 2014 | 194.01 Million CHF | 76.2% |
| 2013 | 110.11 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 185.6 Million CHF | -6.43% |
| 2024 Q2 | 170.61 Million CHF | -8.08% |
| 2023 Q3 | 218.11 Million CHF | -5.37% |
| 2023 Q1 | 244.53 Million CHF | -6.76% |
| 2023 Q2 | 230.49 Million CHF | -5.74% |
| 2023 FY | 198.35 Million CHF | -24.37% |
| 2023 Q4 | 198.35 Million CHF | -9.06% |
| 2022 Q1 | 311.84 Million CHF | 80.6% |
| 2022 Q3 | 281.16 Million CHF | -6.06% |
| 2022 Q4 | 262.25 Million CHF | -6.72% |
| 2022 FY | 262.25 Million CHF | 51.89% |
| 2022 Q2 | 299.29 Million CHF | -4.02% |
| 2021 Q2 | 206.98 Million CHF | 19.62% |
| 2021 Q4 | 172.66 Million CHF | -2.1% |
| 2021 FY | 172.66 Million CHF | -7.93% |
| 2021 Q1 | 173.03 Million CHF | -7.74% |
| 2021 Q3 | 176.36 Million CHF | -14.79% |
| 2020 Q4 | 187.54 Million CHF | 0.0% |
| 2020 FY | 187.54 Million CHF | 78.73% |
| 2020 Q2 | 73.33 Million CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2019 FY | 104.93 Million CHF | -32.37% |
| 2019 Q3 | 104.93 Million CHF | -22.2% |
| 2019 Q1 | 134.88 Million CHF | -13.07% |
| 2019 Q2 | 134.88 Million CHF | 0.0% |
| 2019 Q4 | 104.93 Million CHF | 0.0% |
| 2018 FY | 155.15 Million CHF | 7.43% |
| 2018 Q1 | 127.43 Million CHF | -11.76% |
| 2018 Q4 | 155.15 Million CHF | 0.0% |
| 2018 Q3 | 155.15 Million CHF | 21.75% |
| 2018 Q2 | 127.43 Million CHF | 0.0% |
| 2017 Q3 | 144.42 Million CHF | -10.32% |
| 2017 Q4 | 144.42 Million CHF | 0.0% |
| 2017 FY | 144.42 Million CHF | -21.55% |
| 2017 Q1 | - CHF | -100.0% |
| 2017 Q2 | 161.04 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2016 Q2 | 200.61 Million CHF | 0.0% |
| 2016 Q4 | 184.09 Million CHF | 0.0% |
| 2016 FY | 184.09 Million CHF | -16.09% |
| 2016 Q3 | - CHF | -100.0% |
| 2015 FY | 219.39 Million CHF | 13.08% |
| 2015 Q1 | - CHF | -100.0% |
| 2015 Q4 | 219.39 Million CHF | 0.0% |
| 2015 Q2 | 193.5 Million CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | 194.01 Million CHF | 76.2% |
| 2014 Q4 | 194.01 Million CHF | 0.0% |
| 2013 FY | 110.11 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -10462.549% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -39646.793% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -75816.365% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -1779.401% |
| GB Sciences, Inc. | 103.44 Thousand USD | -191651.9% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2116.433% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1109251.23% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1561.182% |
| Zenith Capital Corp. | 7410.00 USD | -2676715.115% |
| Agentix Corp. | 261.39 Thousand USD | -75782.965% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -10029.359% |
| Biomind Labs Inc. | 73.81 Thousand USD | -268600.47% |
| ContraFect Corporation | 20.67 Million USD | -859.195% |
| CSL Limited | 38.02 Billion USD | 99.478% |
| CytoDyn Inc. | 11.13 Million USD | -1681.178% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -25638.473% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -609.82% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -41175.437% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -273999.357% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -55992.326% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -52.332% |
| SQZ Biotechnologies Company | 107.18 Million USD | -85.052% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -5887.06% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -410.598% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -13751.087% |
| Mesoblast Limited | 667.9 Million USD | 70.302% |
| Marizyme, Inc. | 22.01 Million USD | -800.983% |
| Genus plc | 1.02 Billion USD | 80.722% |
| Pharming Group N.V. | 462.85 Million USD | 57.146% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -31535.088% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -51800.559% |
| IMV Inc. | 31.33 Million USD | -533.029% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -4684.152% |
| MultiCell Technologies, Inc. | 126.22 USD | -157147737.11% |
| ONE Bio Corp. | 70.08 Million USD | -183.014% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -54.348% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -463.836% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -13590.372% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -560.844% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -7122.426% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -28751.788% |
| Alpha Cognition Inc. | 2.45 Million USD | -7988.836% |
| Enzolytics Inc. | 361.7 Million USD | 45.162% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 95.633% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -315.815% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -30909.167% |
| Genscript Biotech Corporation | 3.38 Billion USD | 94.143% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -2647.348% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -259679.448% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -61537.135% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -75791.094% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -21275.036% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -14502.39% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -50711.802% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -21008.26% |
| Helix BioMedix, Inc. | 3.02 Million USD | -6456.904% |
| EV Biologics, Inc. | 431.71 Thousand USD | -45845.232% |
| Q BioMed Inc. | 3.51 Million USD | -5542.186% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -276.372% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 55.557% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1262.28% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -7519.557% |
| HST Global, Inc. | 1526.00 USD | -12998065.138% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -8586566.667% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -19976.784% |
| Halberd Corporation | 10.13 Thousand USD | -1957771.878% |
| Resverlogix Corp. | 8.11 Million USD | -2344.264% |
| Cell Source, Inc. | 195.17 Thousand USD | -101529.853% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -870590.488% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -2588.732% |
| Ember Therapeutics, Inc. | 184.00 USD | -107799900.0% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -318547.989% |
| Kadimastem Ltd | 2.3 Million USD | -8508.729% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -207257.538% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -347313.038% |
| LadRx Corporation | 2.3 Million USD | -8494.547% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -55992.326% |
| Affymax, Inc. | 7.44 Million USD | -2564.947% |
| Itoco Inc. | 1.4 Million USD | -14067.271% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -187024.528% |
| Mobile Lads Corp. | 52.00 USD | -381446053.846% |
| International Stem Cell Corporation | 5.39 Million USD | -3580.0% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -144011.365% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -138634.857% |
| Qrons Inc. | 420.00 USD | -47226566.667% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -51357.049% |
| SYBLEU INC | 330.46 Thousand USD | -59921.545% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -35825.523% |
| Rebus Holdings, Inc. | 5000.00 USD | -3966940.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -48346.835% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1222.185% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1096.405% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -250978.481% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -22839.433% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -2538.712% |
| Neutra Corp. | 2851.00 USD | -6957178.148% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -512.084% |
| PureTech Health plc | 693.97 Million USD | 71.418% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2357.562% |
| IXICO plc | 15.84 Million USD | -1151.914% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2294.977% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -91.971% |
| CSL Limited | 38.02 Billion USD | 99.478% |
| Cellectis S.A. | 333.99 Million USD | 40.612% |